Clinical trials: Atopic Eczema
Atopic Dermatitis
The Role of Confocal Microscopy in Estimating Dupilumab Treatment Response for Moderate/Severe Atopic Dermatitis
Atopic dermatitis (AD) is recognized as the most prevalent chronic inflammatory skin disease across all age groups. The introduction of reflectance confocal microscopy (RCM) signifies a substantial leap forward in the…
- Trial name
- NCT07098000
- Where
- Argentina
- Volunteers
- 40 people, healthy volunteers welcome
- Sponsor
- Hospital Italiano de Buenos Aires
Healthy Volunteers, Atopic Dermatitis
A Study Evaluating the Safety and Efficacy of Topical BPR277 for the Treatment of Atopic Dermatitis and Netherton Syndrome
The study is divided in 3 parts, starting with the safety assessment of BPR277 ointment in Healthy volunteers (Part 1). If found to be well tolerated in Part 1, BPR277 ointment will be assessed in two different patients groups to…
- Conditions
- Healthy Volunteers, Atopic Dermatitis, Netherton Syndrome
- Trial name
- 3 (NCT01428297)
- Testing
- BPR277 ointment (controlled application), BPR277 ointment, BPR277
- Where
- 4 sites in United States, Netherlands
- Volunteers
- 12 people, healthy volunteers welcome
- Sponsor
- Novartis Pharmaceuticals
Itch
Role of Interleukin-13 Pathways on Pain and Itch Sensitivity
Atopic dermatitis (AD) is as chronic, inflammatory skin disorder affecting 20% of the world's population. Intense itch and skin pain are the main symptoms.
- Trial name
- IL-13 (NCT06503510)
- Testing
- Histamine, Cowhage, bovine adrenal medulla (BAM8-22)
- Where
- 3 sites in Denmark
- Volunteers
- 20 people, healthy volunteers welcome
- Sponsor
- Aalborg University
Atopic Dermatitis, Eczema
The Effects of Emollient Therapy on the Skin Barrier
The goal of this study is to better understand what effect emollients (moisturizers) have on the skin in young children and adults.
- Trial name
- EES (NCT01291940)
- Testing
- Pediatric Moisturizer, Adult Moisturizer
- Where
- United States
- Volunteers
- 25 people, healthy volunteers welcome
- Sponsor
- Oregon Health and Science University
Health Adult Subjects, Moderate-to-Severe Atopic Dermatitis
A Phase I Study of HXN5003 in Healthy Participants and Patients With Moderate-to-Severe Atopic Dermatitis
This is a Phase I, multicenter, randomized, double-blind, placebo-controlled study evaluating HXN5003 in healthy participants and patients with moderate-to-severe atopic dermatitis (AD).
- Trial name
- NCT07801612
- Testing
- HXN5003
- Where
- China
- Volunteers
- 68 people, healthy volunteers welcome
- Sponsor
- Helixon Biotechnology (Suzhou) Co., Ltd
Atopic Dermatitis
Clinical vs. Anecdotal Evidence - Pediatric Atopic Dermatitis
In dermatology, topical anti-inflammatory medications, such as corticosteroids, are the mainstay treatment of managing patients with atopic dermatitis.
- Trial name
- NCT03559075
- Where
- United States
- Volunteers
- 480 people, healthy volunteers welcome
- Sponsor
- Wake Forest University Health Sciences
Atopic Dermatitis
A Study to Learn How Different Forms of the Study Medicine Called PF 08049820 Are Taken up Into the Bloodstream in Healthy Adults
The purpose of this study is to see how different forms of a medicine called PF-08049820 move through the body when taken by mouth.
- Trial name
- NCT07172321
- Testing
- PF-08049820 MR1, PF-08049820 MR2, PF-08049820 IR
- Where
- United States
- Volunteers
- 12 people, healthy volunteers welcome
- Sponsor
- Pfizer
Atopic Eczema
A Longitudinal Investigation of Skin Barrier Development From Birth and the Validation of Early Predictors of Atopic Eczema Risk: the Skin Testing for Atopic Eczema Risk (STAR) Study
Eczema is a chronic disease of the skin that is becoming more common worldwide for reasons unknown. Currently the best indicator that a baby will suffer from eczema is if either or both parents have the condition, although this…
- Trial name
- STAR (NCT03143504)
- Testing
- Skin Testing for Atopic eczema
- Where
- United Kingdom
- Volunteers
- 180 people, healthy volunteers welcome
- Sponsor
- Sheffield Teaching Hospitals NHS Foundation Trust
Atopic Dermatitis
Staphylococcus Aureus in Atopic Dermatitis Immunopathology
Atopic Dermatitis (AD) is a frequent inflammatory skin disease characterized by recurrent eczema. It associates genetic/epigenetic-induced alterations of epidermal barrier and type-2 inflammation/hypersensitivity, which may be…
- Trial name
- STADE (NCT04715087)
- Testing
- Blood sample (Day -42 to Day -28, Day 3),Skin swab sampling (Day -42 to Day -28, Day 0, Day 13) , patch test application (Day 0) , skin biopsies (Day 13), Blood sample (Day 0 ,Day 3),Skin swab sampling (Day 0,Day 13), patch test application (Day 1), skin biopsies (Day 13)
- Where
- France
- Volunteers
- 7 people, healthy volunteers welcome
- Sponsor
- Hospices Civils de Lyon
Atopic Dermatitis, Acne Rosacea
Inflammatory Cells From Various Pathologies
The objective of this experiment is to develop and validate in vitro methods to isolate inflammatory cells from skin biopsies for quantitative flow cytometry analysis.
- Conditions
- Atopic Dermatitis, Acne Rosacea, Acne Vulgaris
- Trial name
- NCT02270411
- Where
- Canada
- Volunteers
- 95 people, healthy volunteers welcome
- Sponsor
- Innovaderm Research Inc.
Atopic Dermatitis
Effects of Tralokinumab in the Skin: an Immunologic and Molecular Investigation
The clinical efficacy of tralokinumab has been demonstrated in the treatment of AD; its MOA however remains insufficiently understood.
- Trial name
- TRALIS (NCT05378698)
- Testing
- Application of Tralokinumab
- Where
- Switzerland
- Volunteers
- 24 people, healthy volunteers welcome
- Sponsor
- University of Zurich
Atopic Diathesis, Eczema-Prone Skin
Assessment of Skin Tolerance and Efficacy of a Cosmetic Product After 4 Weeks of Use on Subjects With Atopic Dermatitis
The aim of this study is to compare the efficacy and tolerability of a cosmetic product to one that is already available on the market (benchmark product).
- Trial name
- NCT05786976
- Testing
- Lotion BNO 3732, Body Lotion Benchmark product
- Where
- Germany
- Volunteers
- 44 people, healthy volunteers welcome
- Sponsor
- Bionorica SE
Atopic Dermatitis
A Clinical Study of HRS-8797 in Healthy Participants
The purpose of this phase I study is to evaluate the safety, tolerability, pharmacokinetics and pharmacodynamics of HRS-8797 in healthy participants.
- Trial name
- NCT07698756
- Testing
- HRS-8797
- Where
- China
- Volunteers
- 74 people, healthy volunteers welcome
- Sponsor
- Chengdu Suncadia Medicine Co., Ltd.
Allergic Asthma, Atopic Dermatitis
A Phase 1, Randomized, Placebo-controlled, Dose-escalation Safety Study of MEDI4212 in Subjects With IgE >= 30 IU/mL
Phase 1 study to evaluate the safety of MEDI4212.
- Conditions
- Allergic Asthma, Atopic Dermatitis, Allergic Rhinitis, Healthy Volunteers
- Trial name
- NCT01544348
- Testing
- Omalizumab, MEDI4212 5 mg Subcutaneous, MEDI4212 15 mg Subcutaneous
- Where
- 7 sites in United States
- Volunteers
- 295 people, healthy volunteers welcome
- Sponsor
- MedImmune LLC
Atopic Dermatitis
A Study of Two Different Formulations of 611 in Healthy Adult Subjects in China
The main purpose of this study is to compare two different formulations (mixtures) of 611 in healthy participants. This study will compare how much of each formulation gets into the blood stream.
- Trial name
- 611 (NCT07042113)
- Testing
- new formulations of 611, existing formulations of 611
- Where
- 2 sites in China
- Volunteers
- 180 people, healthy volunteers welcome
- Sponsor
- Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd.
Atopic Dermatitis
Study the Safety and Efficacy of DBI-001 Gel Versus Aqueous Gel
The purpose for this study is to assess the Safety and Efficacy of Daily Application for 4 weeks of DBI-001 Gel Versus Aqueous Gel in Subjects with Atopic Dermatitis
- Trial name
- NCT05253755
- Testing
- DBI-001, Aqueous gel
- Where
- 3 sites in United States
- Volunteers
- 10 people, healthy volunteers welcome
- Sponsor
- DermBiont, Inc.
Atopic Dermatitis
Study of the Skin Microbiome and the Potential of a Topical Probiotic Cream for Atopic Dermatitis
The skin microbiome of atopic dermatitis patients and healthy volunteers will be studies by collecting and analysing skin swabs on different timepoint.
- Trial name
- NCT04771910
- Testing
- Topical cream with live probiotic bacteria
- Where
- Belgium
- Volunteers
- 40 people, healthy volunteers welcome
- Sponsor
- University Hospital, Antwerp
Atopic Dermatitis
Improvement of Short Term Outcome of Mild to Moderate Atopic Dermatitis Using a Combination of Crisaborole and a Concomitant Topical Corticosteroid Over a 8 Week Period
This trial is a single-center two arm, open label observational prospective study, that will evaluate the safety and efficacy of crisaborole ointment, 2% alone compared to a combination therapy of crisaborole and a topical…
- Trial name
- NCT04008784
- Testing
- Crisaborole 2% Topical Application Ointment [EUCRISA], Triamcinolone Acetonide 0.1% Ointment
- Where
- United States
- Volunteers
- 16 people, healthy volunteers welcome
- Sponsor
- Clinical Research Center of the Carolinas
Atopic Dermatitis, Psoriasis
The Role of Bacterial Toxins in Human Skin Disease
Atopic dermatitis and psoriasis are two skin diseases often associated with bacterial infections and inflammation. Studies indicate that skin cells from these patients may have some changes that make these patients more…
- Trial name
- NCT02910791
- Where
- United States
- Volunteers
- 100 people, healthy volunteers welcome
- Sponsor
- National Jewish Health
Healthy Volunteer, Atopic Dermatitis
A Single and Multiple Ascending Dose Trial of KT-474 in Healthy Adult Volunteers and Patients With Atopic Dermatitis (AD) or Hidradenitis Suppurativa (HS)
KT-474 is an oral heterobifunctional small molecule IRAK4 degrader being developed for the treatment of interleukin-1 receptor (IL-1R)/toll-like receptor (TLR)-driven immune-inflammatory diseases.
- Conditions
- Healthy Volunteer, Atopic Dermatitis, Hidradenitis Suppurativa
- Trial name
- NCT04772885
- Testing
- KT-474
- Where
- 14 sites in United States
- Volunteers
- 154 people, healthy volunteers welcome
- Sponsor
- Kymera Therapeutics, Inc.